Schedule 13G ownership disclosure

Mirati Therapeutics Inc

Security class unavailable · CUSIP: 60468T105

Event date: 2017-09-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,748,101
Percent of class
14.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-17-003881
Form type
SC 13G/A
Filer
Mirati Therapeutics, Inc.
CIK
CIK 1576263
Filed
Oct 03, 2017
Reporting period
Sep 30, 2017
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub